Literature DB >> 8109895

Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation.

D B Drachman1, V Chaudhry, D Cornblath, R W Kuncl, A Pestronk, L Clawson, E D Mellits, S Quaskey, T Quinn, A Calkins.   

Abstract

Although the cause of amyotrophic lateral sclerosis (ALS) remains unknown, recent studies have suggested an autoimmune mechanism of pathogenesis. Previous trials of immunosuppressive treatment have yielded inconclusive results. Our study was designed to determine whether more powerful and prolonged immunosuppression, produced by total lymphoid irradiation (TLI), would alter the course of ALS. In a double-blind, randomized, placebo-controlled study, 30 patients with classic ALS were treated with TLI, and 31 were given sham radiation. Quantitative measurements of muscle strength, functional motor activity, and humoral and cellular immune status were followed for 2 years, or until death or respirator dependence. Motor function in the TLI-treated and control groups showed no significant differences throughout the study. Overall survival was not significantly different in the TLI-treated and control groups. TLI effectively suppressed cellular and humoral immune function throughout the 2-year study period. Analysis of the relationship between immunosuppression and motor functions showed no consistent effect of treatment. We conclude that powerful and prolonged immunosuppression produced by TLI did not benefit patients with ALS. This fails to support the concept of an autoimmune mechanism of pathogenesis of ALS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8109895     DOI: 10.1002/ana.410350205

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  21 in total

Review 1.  Treatment of amyotrophic lateral sclerosis.

Authors:  A Eisen; M Weber
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

2.  Amyotrophic Lateral Sclerosis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

Review 3.  Measures and markers in amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Muhammad Qureshi; Jeremy Shefner
Journal:  NeuroRx       Date:  2004-04

Review 4.  Amyotrophic lateral sclerosis: current and future treatment strategies.

Authors:  B W Festoff
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 5.  Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia.

Authors:  Deepti Lall; Robert H Baloh
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

6.  Impact of peripheral immune status on central molecular responses to facial nerve axotomy.

Authors:  D O Setter; E M Runge; N D Schartz; F M Kennedy; B L Brown; K P McMillan; W M Miller; K M Shah; M M Haulcomb; V M Sanders; K J Jones
Journal:  Brain Behav Immun       Date:  2017-10-10       Impact factor: 7.217

Review 7.  Immunological findings in amyotrophic lateral sclerosis.

Authors:  J P Antel; N R Cashman
Journal:  Springer Semin Immunopathol       Date:  1995

Review 8.  Motor neuron disease.

Authors:  P N Leigh; K Ray-Chaudhuri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

9.  Immunological aspects in amyotrophic lateral sclerosis.

Authors:  Maria Carolina O Rodrigues; Júlio C Voltarelli; Paul R Sanberg; Cesario V Borlongan; Svitlana Garbuzova-Davis
Journal:  Transl Stroke Res       Date:  2012-05-03       Impact factor: 6.829

Review 10.  Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:  Michel Dib
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.